BEIJING, Aug. 30, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ:LIFE), a U.S.-based global biotechnology leader, and Sino Biological Inc., a leading Chinese biotech company, today announced a partnership for worldwide product distribution and product development. Life Technologies will distribute Sino Biological's extensive portfolio of recombinant proteins, antibodies and Elisa kits utilizing its global distribution channels. The two companies will also jointly develop new products, leveraging R&D synergies to introduce innovative products more quickly. By partnering with one another, the companies are well positioned to provide proteomics products to a global customer base, and as two of the leading life science brands in China, contribute to accelerating growth of the Chinese biotech industry.
Global Distribution Channels and Innovative New Product Offerings for Dynamic Proteomics Market
"The collaboration presents a tremendous opportunity to offer a robust proteomics portfolio to meet customer needs in this highly dynamic global market," said Gregory T. Lucier, Chairman and CEO of Life Technologies. "Through this collaboration we plan to leverage our strong brands, worldwide commercial reach and technology support with Sino Biological's world leading technologies to develop solutions for scientists worldwide who are tackling important healthcare challenges such as cancer, diabetes and heart disease."
"Sino Biological's mission is to develop the best quality biological tools to assist scientists," said Dr. Liangzhi Xie, president and CEO of Sino Biological. "Combining our state-of-the-art, disruptive technologies in recombinant protein production and antibody development with Life Technologies' innovative product development and worldwide marketing, will allow us to bring powerful research tools to scientists solving critical puzzles in life science research and drug discovery."Partnership of Two Leading Life Science Brands Accelerates Growth of Chinese Science and Biotechnology "Life Technologies is committed to supporting growth of China's biotech industry," said Dr. Siddhartha Kadia, Life Technologies President, Greater China. "We are delighted to partner with Sino Biological to distribute more than 6000 human-derived proteins and antibodies. These products provide high quality and exceptional value, complementing the well- recognized Novex® and Gibco® branded reagents from Life Technologies." Proteins and antibodies represent a fundamental tool employed by pharmaceutical researchers and academic scientists to facilitate the discovery of novel therapeutic targets in the process of drug development. Proteins and antibodies are also used to culture cells for basic research, drug discovery and production, and development of novel therapeutics such as stem cells. The agreement calls for joint development of proteomic products for additional applications including flow cytometry and imaging technologies.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts